Stockholders' Equity - Additional Information (Details)

v3.25.1

Stockholders' Equity - Additional Information (Details) - USD ($)												3 Months Ended		9 Months Ended
	Mar. 03, 2025	Feb. 24, 2025	Mar. 28, 2024	Mar. 14, 2024	Nov. 17, 2023	Nov. 15, 2023	Nov. 13, 2023	Nov. 09, 2023	May 25, 2023	Aug. 03, 2022	Aug. 01, 2022	Mar. 31, 2025	Mar. 31, 2024	Sep. 30, 2024	Mar. 22, 2025	Dec. 31, 2024	Dec. 23, 2024	May 31, 2024	Apr. 25, 2024	Mar. 25, 2024	Feb. 14, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized											70,000,000	70,000,000				70,000,000
Preferred stock, shares authorized											30,000,000	30,000,000				30,000,000
Common stock, par value												$ 0.0001				$ 0.0001
Warrants exercise price, per share											$ 6.25
Stock options outstanding												10,904,814				9,769,992
Fair value assumptions, contractual term												7 years
Exercise price percentage												110.00%
Percentage of shares granted												10.00%
Warrants and rights exercisable period											Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire											Jul. 27, 2027
Loss (gain) on remeasurement of warrant liability												$ (825,989)	$ 4,181,298
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate										2.82%
Volatility rate										77.50%
Fair value assumptions, contractual term										5 years
Warrants										$ 343,735
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												10 years
Warrants to purchase aggregate of common stock											100,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0
Stock options outstanding												1,773,912
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance												0
Stock options outstanding												3,503,589
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance											1,909,518	2,723,686				2,250,000						2,838,668	1,956,993
Stock options outstanding												5,627,313
Percentage of increase in stock outstanding fully diluted									10.00%
IPO | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants												$ 45,404				$ 71,672
Loss (gain) on remeasurement of warrant liability												$ (26,268)	$ 72,666
Overallotment Option | Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock										15,000
At The Market Offering Agreement | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value																					$ 0.0001
Number of common stock Issued and sold												666,323	507,754
Common stock per share												$ 2.28	$ 1.47
Gross proceeds from sale of common stock												$ 1,521,091	$ 745,251
Commissions paid												45,633	22,357
Issuance costs												84,587	157,271
Net proceeds from common stock												$ 1,390,871	565,623
Private Placement
Subsidiary or Equity Method Investee [Line Items]
Common stock per share	$ 1.5	$ 1.5
Aggregate purchase price	$ 1,400,000	$ 2,700,000
Warrants exercise price, per share				$ 1.3
Warrants and rights exercisable period		Feb. 24, 2031		Sep. 14, 2024
Class of warrant or right date from which warrants or rights expire				Sep. 14, 2029
Warrants													3,793,921					$ 5,089,063
Loss (gain) on remeasurement of warrant liability													1,744,321
Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate				4.20%
Volatility rate				95.00%
Fair value assumptions, contractual term				5 years 6 months
Warrants				$ 2,049,600
Private Placement | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants																		$ 437,031
Private Placement Offering 1 | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants													973,980
Loss (gain) on remeasurement of warrant liability													(216,131)
Private Placement Offering 1 | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Remaining warrant liability												141,612
Warrants												$ 144,790				199,417
Loss (gain) on remeasurement of warrant liability												(54,627)
Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock																		437,031
Warrants and rights exercisable period	Mar. 03, 2026	Feb. 24, 2026	Sep. 28, 2024
Class of warrant or right date from which warrants or rights expire	Mar. 03, 2031	Feb. 24, 2031	Sep. 28, 2029
Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate			4.20%
Volatility rate			95.00%
Fair value assumptions, contractual term			5 years 6 months
Warrants			$ 1,190,111
Private Placement Offering | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants												1,011,562						$ 1,011,562
Registered Direct Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share					$ 1.86	$ 2.06
Risk free interest rate					3.85%	3.84%
Volatility rate					90.00%	90.00%
Fair value assumptions, contractual term					5 years 4 months 17 days	4 years 10 months 17 days
Warrants to purchase aggregate of common stock						169,697
Warrants and rights exercisable period						Nov. 15, 2023
Class of warrant or right date from which warrants or rights expire						Nov. 15, 2028
Warrants					$ 1,903,915	$ 123,811						164,492				230,038
Loss (gain) on remeasurement of warrant liability												(65,546)	156,959
Registered Direct Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold														458,726
Issuance of common shares upon cashless exercise of warrants, shares														909,091
Warrants					2,815,970							1,509,930				2,189,478
Increase in equity on exercise of warrant liability					$ 2,815,970
Loss (gain) on remeasurement of warrant liability												$ (679,548)	$ 2,307,832
Registered Direct Offering | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock					2,424,243
Directors | Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate				4.20%
Volatility rate				95.00%
Fair value assumptions, contractual term				5 years 6 months
Warrants				$ 230,685
Directors | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	3.97%	4.23%
Volatility rate	95.00%	95.00%
Fair value assumptions, contractual term	6 years	6 years
Warrants	$ 80,894	$ 176,680
Common Stock | At-the-Market Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold												666,323	507,754
Common Stock | At The Market Offering Agreement | Maximum | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Aggregate offering price															$ 11,200,000		$ 30,000,000			$ 4,950,000	$ 1,445,000
Common Stock | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	952,633	1,810,000		2,496,318
Common Stock | Private Placement Offering 1
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold													2,496,318
Common Stock | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold												2,762,633
Common Stock | Directors | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	58,333	123,333
Common Stock | Directors | Private Placement Offering | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold				452,731
Common Stock | Non-Affiliated Investors | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	894,300			2,043,587
Common Stock | Affiliated and Non-affiliated Investors | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold		1,686,667
Investor Warrants | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	952,633	1,810,000
Common stock per share	$ 1.85	$ 1.87																	$ 1.85
Investor Warrants | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	952,633	1,686,667	578,643
Common stock per share		$ 1.87																			$ 2.55
Oustside Investors Warrants | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	3.97%	4.23%
Volatility rate	95.00%	95.00%
Fair value assumptions, contractual term	6 years	6 years
Warrants	$ 1,240,185	$ 2,416,223
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense												$ 0	$ 11,500
Shares granted												0	12,500
Unvested shares												0	0
Alumni Capital LP
Subsidiary or Equity Method Investee [Line Items]
Warrants exercise price, per share								$ 2.09
Risk free interest rate								3.93%
Volatility rate								90.00%
Fair value assumptions, contractual term								3 years 10 months 13 days
Warrants and rights exercisable period								Nov. 10, 2023
Class of warrant or right date from which warrants or rights expire								Nov. 10, 2027
Warrants								$ 84,251
Warrant shares vested							131,578
Alumni Capital LP | Laidlaw & Company Ltd
Subsidiary or Equity Method Investee [Line Items]
Warrant fee paid in cash								$ 13,750
Warrants and rights exercisable period								May 22, 2024
Issuance of common shares upon cashless exercise of warrants, shares							54,976
Warrants								$ 375,705				$ 0	$ 199,902			$ 0
Loss (gain) on remeasurement of warrant liability													$ 115,651
Alumni Capital LP | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock								239,234